Expression of the lipogenic enzyme fatty acid synthase (FAS) in retinoblastoma and its correlation with tumor aggressiveness

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 6, 2003, Pages 2399-2403

  Camassei, Francesca Diomedi ^a   Cozza, Raffaele ^a   Acquaviva, Antonio ^c   Jenkner, Alessandro ^a   Ravà, Lucilla ^a   Gareri, Roberta ^a   Donfrancesco, Alberto ^a   Bosman, Cesare ^b   Vadalà, Pasquale ^a   Hadjistilianou, Theodora ^c   Boldrini, Renata ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID SYNTHASE;

ARTICLE; CANCER INVASION; CANCER STAGING; CELL DEATH; CHILD; CHOROID; CONTROLLED STUDY; FATTY ACID SYNTHESIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MICROPHTHALMIA; MITOSIS RATE; OPTIC NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINOBLASTOMA; STATISTICAL ANALYSIS; TUMOR DIFFERENTIATION;

CHILD; CHILD, PRESCHOOL; FATTY ACID SYNTHETASE COMPLEX; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; MALE; MITOTIC INDEX; NEOPLASM INVASIVENESS; RETINAL NEOPLASMS; RETINOBLASTOMA; RETROSPECTIVE STUDIES;

EID: 0038823867     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-0934     Document Type: Article

References (43)

1. McLean IW, Burnier MN, Zimmerman LE, Jakobiec FA. Tumors of the retina. In: Tumors of the Eye and Ocular Adnexa. Washington, DC: Armed Forces Institute of Pathology; 1994:97-149.
2. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol. 2000;18:12-17.
3. Shouten-van Meeteren AYN, Moll AC, Imhof SM, Veerman AJP. Chemotherapy for retinoblastoma: an expanding area of clinical research. Med Pediatr Oncol. 2002;38:428-438.
4. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology. 1999;106:1947-1950.
5. Mendelsohn ME, Abramson DH, Madden T, et al. Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arcb Ophthalmol. 1998;115:1286-1290.
6. Brichard B, De Bruycker JJ, De Potter P, Neven B, Vermylen C, Cornu G. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma. Med Pediatr Oncol. 2002;38:411-415.
7. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 2000;16:202-208.
8. Ohlrogge J, Pollard M, Bao X, et al. Fatty acid synthesis: from CO2 to functional genomics. Biochem Soc Trans. 2000;28:567-573.
9. Latasa MJ, Moon YS, Kim KH, Sul HS. Nutritional regulation of the fatty acid synthase promoter in vivo: sterol regulatory element binding protein functions through an upstream region containing a sterol regulatory element. Proc Natl Acad Sci USA. 2000;97: 10619-10624.
10. Weiss L, Hoffman G, Schreiber R, et al. Fatty-acid biosynthesis in man, a pathway of minor importance. Biol Chem. 1986;367:905- 912.
11. Kusakabe T, Maeda M, Hoshi N, et al. Fatty acid synthase is expressed mainly in adult hormone-sensitive cells or cells with high lipid metabolism and in proliferating fetal cells. J Histochem Cytochem. 2000;48:613-622.
12. Wilentz RE, Witters LA, Pizer ES. Lipogenic enzymes fatty acid synthase and acetyl-coenzyme A carboxylase are coexpressed with sterol regulatory element binding protein and Ki-67 in fetal tissues. Pediatr Dev Pathol. 2000;3:525-531.
13. Alò PL, Visca P, Marci A, et al. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer. 1996;77:474-482.
14. Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP. Enzymes of the fatty acid pathways are highly expressed in in situ breast cancer. Clin Cancer Res. 1997;3:2115-2120.
15. Wang Y, Kuhajda FP, Li JN, et al. Fatty acid synthase (FAS) expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett. 2001;167:99-104.
16. Shurbaji MS, Kuhajda FP, Pasternack GR, Thurmond TS. Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression in prostate cancer. Hum Pathol. 1996; 27:917-921.
17. Myers RB, Oelschlager DK, Weiss HL, et al. Fatty acid synthase: an early molecular marker of progression of prostatic adenocarcinoma to androgen independence. J Urol. 2001;165:1027-1032.
18. Swinnen JV, Vanderhoydonc F, Elgamal AA, et al. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer. 2000;88:176-179.
19. Swinnen JV, Roskams T, Joniau S, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer. 2002;98:19-22.
20. Rashid A, Pizer ES, Moga M, et al. Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol. 1997;150:201-208.
21. Gansler TS, Hardman W, Hunt DA, et al. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol. 1997;28:686-692.
22. Pizer ES, Lax S, Kuhajda FP, et al. Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Cancer. 1998;83:528-537.
23. Gabrielson EW, Pinn ML, Testa JR, Kuhajda FP. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res. 2001;7:153-157.
24. Vlad LD, Axiots CA, Merino MJ, et al. Fatty acid synthase is highly expressed in aggressive thyroid tumors (Abstract). Mod Pathol. 1999; 12:70A.
25. Piyathilake CJ, Frost AR, Manne U, et al. The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol. 2000;31:1068-1073.
26. Kusakabe T, Nashimoto A, Honma K, Suzuki T. Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. Histopathology. 2002;40:71-79.
27. Li JN, Gorospe M, Chrest FJ, et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res. 2001;61:1493-1499.
28. Huang PL, Zhu SN, Lu SL, Dai ZS, Jin YL. Inhibitor of fatty acid synthase induced apoptosis in human colonic cancer cells. World J Gastroenterol 2000;6:295-297.
29. Pizer ES, Thupari J, Han WF, et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. 2000;60:213-218.
30. Thupari JN, Pinn ML, Kuhajda FP. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun. 2001;285:217-223.
31. Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB. Increased fatty acid synthase as a therapeutic target in androgen independent prostate cancer progression. Prostate. 2001;47:102-110.
32. Kuhajda FP, Pizer ES, Li JN, et al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA. 2000;97:3450-3454.
33. Pizer ES, Wood FD, Heine HS, et al. Inhibition of fatty acid synthase delays disease progression in a xenograft model of ovarian cancer. Cancer Res. 1996;56:1189-1193.
34. Pizer ES, Chrest FJ, Di Giuseppe JA, et al. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res. 1998;58: 4611-4615.
35. Furuya Y, Akimoto S, Yasada K, et al. Apoptosis of androgen-independent prostate cell line induced by inhibition of fatty acid synthesis. Anticancer Res. 1997;17:4589-4593.
36. Pizer ES, Jackisch C, Wood FD, et al. Inhibition of fatty acid synthase induces programmed cell death in human breast cancer cells. Cancer Res. 1996;56:2745-2747.
37. Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES. Activation of fatty acid synthase during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res. 2002;279:80-90.
38. Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV. Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res. 2002;62:642-646.
39. Swinnen JV, Heemer H, Deboel L, Foufelle F, Heyns W, Verhoeven G. Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene. 2000;19:5173-5181.
40. Wang Y, Kuhajda FP, Sokoll LJ, et al. Two-site ELISA for the quantitative determination of fatty acid synthase. Clin Chim Acta. 2001;304:107-115.
41. Chan HS, DeBoer G, Thiessen JJ, et al. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res. 1996;2:1499-1508.
42. Chan HS, Lu Y, Grogan TM, et al. Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res. 1997;57:2325-2330.
43. Chan HS, Thorner PS, Haddad G, Gallie BL. Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression. Ophthalmology. 1991;98:1425-1431.